Cancer diagnosis by the measurement of Nup88 in body samples

Details Cancer diagnosis by the measurement of Nup88 in body samples Cancer diagnosis by the measurement of Nup88 in body samples

2006-04-18

2006-04-18

Rawlings, Stephen L. (Department: 1643)

Chemistry: molecular biology and microbiology

Measuring or testing process involving enzymes or...

Involving antigen-antibody binding, specific binding protein...

C530S350000, C530S387300, C530S387700, C530S387900, C530S388800, C435S330000, C435S331000, C536S024310, C536S024330, C436S064000

Reexamination Certificate

active

07029866

ABSTRACT:
The invention is directed to a method of diagnosis of the existence and/or the pathological developmental stage and/or the grade of malignancy of carcinomas and/or sarcomas in mammals characterized by the preparation of a body sample of said mammals and the determination of the overexpression of the protein Nup88 in said sample and to antibodies suitable for performing the same.

REFERENCES:
patent: 5356817 (1994-10-01), Cole
patent: 5366866 (1994-11-01), Xu et al.
patent: 5585089 (1996-12-01), Queen et al.
patent: 6312908 (2001-11-01), Wahl et al.
patent: 6441143 (2002-08-01), Koski
patent: 6682901 (2004-01-01), Blaschuk et al.
Campbell AM. Monoclonal Antibody Technology, Laboratory Techniques in Biochemistry and Molecular Biology, Elsevier Science Publishers B.V.: Amsterdam, The Netherlands, vol. 13, pp. 1-32.
Fornerod M, et al. Genomics. 1997; 42: 538-40.
Fornerod M, et al. EMBO J. Feb. 17, 1997; 16 (4): 807-16.
Mariuzza RA, et al. Annu Rev Biophys Biophys Chem. 1987; 16: 139-59.
Gould VE, et al. Am J Pathol. Nov. 5, 2000; 157 (5): 1605-13.
Boer JM, et al. Exp Cell Res. 1997; 232: 182-5.
Bastos R, et al. J Cell Biol. Jun. 2, 1997; 137 (5): 989-1000.
Matsuoka Y, et al. Biochem Biophys Res Commun. 1999; 254: 417-23.
Alberts et al (Molecular BIology of the Cell, 3rd Ed., 194, p. 465).
Shantz and Pegg (Int J. of BIochem and Cell Biol., 1999, 31:107-122).
McClean and Hill (Eur. J. Can, 1993, 29A:2243-2248).
Fu et al (EMBO Journal, 1996, 15:4392-4401).
Yokota et al (Oncogene, 1988, 3:471-475).
Bowie et al (Science, 1990, 247:1306-1310).
Gussow et al (Methods in Enzymology, 1991, 203:99-121).
Rudikoff et al., (PNAS, USA, 1982, 79:1979).
Roitt et al, Immunology, 4t Ed., 1998, Mosby, London, p. 7.7-7.8).
Holmes (Exp. Opin. Invest. Drugs, 2001, 10(3):511-519).
Boehringer Mannheim Biochemicals, 1994 Catalog, p. 93.
Oberg, A, et al, Limited value of preoperative serum analyses of matrix metalloproteinases (MMP-2, MMP-9) and tissue inhibitors . . . Anticancer Research, vol. 20, No. 2B, pp. 1085-1091 (abstract only, PubMed ID: 10810401).
Tockman, MS, et al, 1992, Considerations in bringing a cancer biomarker to clinical application, Cancer Research, vol. 52, Suppl., pp. 2711s-2718s.
Ward, AM, 1985, Tumour Markers, Developmental Oncology, vol. 21, pp. 90-106.
Pohl, AL, et al, 1994, Neural network evaluation of multiple tumor markers for diagnosis of ovarian cancer (meeting abstract), Non-serial, 3rd International Conference of the Mediterranean Society of Tumor Marker Oncology, CANCERLIT Accession No. 95614997.
Genesis Group Associates, Inc., 1997, New tests improve breast cancer prognosis, Genesis Report-Dx, vol. 6, No. 3, NLDB Accession No. 97:320100.
Martinez et al., “The Nuclear Pore Complex Protein Nup88 Is Overexpressed In Tumor Cells”,Cancer Research,National Library of Medicine, vol. 59:5408-5411, (1999).
Yasumoto et al., “Cancer-Specific Binding Of A Mouse MAb vs. Candida Krusei Cytochrome c: An antigen Recognized By A Cancer-Associated Human MAb HB4C5”,Hum. Antibod. Hybridomas,Butterworth-Heinemann, vol. 4:186-189, (1993).
Schneider et al., “Cross-Reactivity BetweenCandida albicansAnd Human Ovarian Carcinoma As Revealed By Monoclonal antibodies PA10F and C6”,British Journal of Cancer,Cancer Research Campaign, vol. 77(6):1015-1020, (1998).
van Deursen et al., “G2 Arrest And Impaired Nucleocytoplasmic Transport In Mouse Embryos Lacking The Proto-Oncogene CAN/Nup214”,The EMBO Journal,Ocford University Press, vol. 15(20):5574-5583, (1996).
von Lindern et al., “The Translocation (6;9), Associated With A Specific Subtype Of Acute Myeloid Specific Leukemia, Results In The Fusion Of Two Genes, dek and can, And The Expression Of A Chimeric, Leukemia-dek-can mRNA”,Molecular And Cellular Biology,American Society For Microbiology, vol. 12(4):1687-1697, (1992).
von Lindern et al., “can, A Putative Oncogene Associated With Myeloid Leukemogenesis, May Be Activated By Fusion Of Its 3' Half To Different Genes: Characterization of the Set Gene”, American Society For Microbiology, vol. 12(8):3346-3355, (1992).

Affiliated with

Also associated with

Rating

Cancer diagnosis by the measurement of Nup88 in body samples does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Cancer diagnosis by the measurement of Nup88 in body samples, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cancer diagnosis by the measurement of Nup88 in body samples will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3594207